Satellos Bioscience Advances to Clinical Stage with DMD Drug Candidate SAT-3247

Satellos Bioscience has submitted a regulatory filing to commence a Phase 1 clinical trial for SAT-3247, its novel oral drug candidate for Duchenne muscular dystrophy (DMD).

Key points:

  • Satellos submitted a clinical research proposal to an Australian Human Research Ethics Committee on July 10, 2024, seeking authorization for a first-in-human Phase 1 trial of SAT-3247.
  • SAT-3247 is designed to restore impaired muscle regeneration in DMD through a dystrophin-independent pathway.
  • If successful, Satellos plans to advance SAT-3247 into clinical trials with DMD patients in early 2025.

Market estimate: The global Duchenne Muscular Dystrophy treatment market was valued at $1.01 billion in 2021 and is projected to reach $4.11 billion by 2030, growing at a CAGR of 16.8% from 2022 to 2030, according to Allied Market Research.

___________________________________

Satellos Takes Crucial Step Towards DMD Treatment

Satellos Bioscience Inc. has marked a significant milestone in its journey to develop a novel treatment for Duchenne muscular dystrophy (DMD). The company has submitted a regulatory filing to commence a Phase 1 clinical trial for its lead drug candidate, SAT-3247.

Innovative Approach to Muscle Regeneration

SAT-3247 represents a new approach to treating DMD. Unlike traditional therapies that focus on restoring dystrophin production, SAT-3247 aims to restore the process of muscle repair and regeneration by regulating a dystrophin-independent pathway. This unique mechanism of action could potentially benefit DMD patients regardless of their genetic mutation or ambulatory status.

From Preclinical Success to Clinical Trials

The submission of the clinical research proposal follows successful preclinical studies. Phil Lambert, Ph.D., Chief Scientific Officer of Satellos, expressed confidence in the preclinical results and the company’s readiness to move into clinical development. The proposed Phase 1 trial will assess the safety and pharmacokinetic properties of SAT-3247 in healthy volunteers.

Looking Ahead

If the Phase 1 trial is successful, Satellos plans to advance SAT-3247 into clinical trials with DMD patients in early 2025. This progression could mark a significant step forward in the treatment of DMD, potentially offering new hope to patients and families affected by this devastating disease.

Source: Businesswire

Satellos logo

Subscribe

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

BioMediaHub Logo